AK112 + tinengotinib

**AK112 + tinengotinib** is an investigational combination therapy composed of the bispecific antibody **AK112** (cadonilimab), which targets programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), and **tinengotinib** (TT-00420), a spectrum-selective, oral multi-kinase inhibitor. AK112 is designed to block both immune checkpoint PD-1 and angiogenic factor VEGF, thereby enhancing anti-tumor immune activity and inhibiting tumor angiogenesis. Tinengotinib targets multiple kinases important in cancer progression, including fibroblast growth factor receptors 1-3 (FGFR1–3), Janus kinase 1/2 (JAK1/2), vascular endothelial growth factor receptors (VEGFRs), and Aurora kinases A/B. The combination is under investigation primarily for advanced solid tumors including cholangiocarcinoma (bile duct cancer) and potentially other cancers, where resistance to other therapies or enhanced efficacy may be achieved by dual checkpoint and multikinase blockade[1][2][3][4][7].

Brand names

cadonilimab

Other names

tinengotinibTT-00420TT00420TT 00420AK112AK-112AK 112